Last reviewed · How we verify
Placebo transdermal two 90 μL sprays — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo transdermal two 90 μL sprays (Placebo transdermal two 90 μL sprays) — Lumara Health, Inc.. This drug does not have a known mechanism of action.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo transdermal two 90 μL sprays TARGET | Placebo transdermal two 90 μL sprays | Lumara Health, Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo transdermal two 90 μL sprays CI watch — RSS
- Placebo transdermal two 90 μL sprays CI watch — Atom
- Placebo transdermal two 90 μL sprays CI watch — JSON
- Placebo transdermal two 90 μL sprays alone — RSS
Cite this brief
Drug Landscape (2026). Placebo transdermal two 90 μL sprays — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-transdermal-two-90-l-sprays. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab